

Correspondence

Citation for published version (APA):

van de Laar, R., Kruitwagen, R. F. P. M., Zusterzeel, P. L. M., Van Gorp, T., & Massuger, L. F. A. G. (2017). Correspondence: Premature Stop of the SOCceR Trial, a Multicenter Randomized Controlled Trial on Secondary Cytoreductive Surgery Netherlands Trial Register Number: NTR3337. *International Journal of Gynecological Cancer*, 27(1), 2-2. <https://doi.org/10.1097/IGC.0000000000000841>

Document status and date:

Published: 01/01/2017

DOI:

[10.1097/IGC.0000000000000841](https://doi.org/10.1097/IGC.0000000000000841)

Document Version:

Publisher's PDF, also known as Version of record

Document license:

Taverne

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

**Correspondence: Premature
Stop of the SOCceR
Trial, a Multicenter
Randomized Controlled
Trial on Secondary
Cytoreductive Surgery
Netherlands Trial Register
Number: NTR3337**

In July 2012, we started the multicenter randomized controlled phase III Surgery Ovarian Cancer Recurrence (SOCceR) trial to assess whether secondary cytoreductive surgery followed by chemotherapy versus treatment with chemotherapy alone increases progression-free survival in patients with recurrent platinum-sensitive epithelial ovarian cancer.¹ All nine gynecological oncology centers and their affiliated hospitals in the Netherlands participated. In total, 230 patients, 18 years or older, with first recurrence of platinum-sensitive (≥ 6 months after completion of frontline platinum-taxol chemotherapy) epithelial ovarian cancer had to be included. From the start of the trial until the premature stop in August 2015, only 27 (11.7%) of the 230 patients needed for completion of this trial were included. There are a number of possible reasons for this lagging inclusion. First, patients with recurrent ovarian cancer and eligible for secondary cytoreductive surgery were operated on outside the SOCceR trial because of a strong belief in secondary cytoreductive surgery among Dutch gynecological oncologists. On the other hand, some eligible patients were also not included because Dutch medical oncologists seem to have a less strong faith in secondary cytoreductive surgery. Second, serum Cancer Antigen 125 (CA125) monitoring after primary treatment was abandoned in the Netherlands after publication of the OV05/EORTC 55955 study.² In this study, there was no survival benefit of an early start of treatment for relapsed ovarian cancer when the

detection was based on a raised CA125 concentration alone. Not performing CA125 monitoring might have resulted in relatively late detection of recurrent ovarian cancer which, in turn, might have reduced the possibility to perform secondary cytoreductive surgery. This finding has led to a renewed discussion toward the early detection of recurrent disease with CA125 in the follow-up of patients with ovarian cancer. Especially when taking into account that only a minority of the patients (7%) in the OV05/EORTC 55955 trial was treated with secondary cytoreductive surgery, which makes the conclusion of the study not generalizable to patients who are possible candidates for relapse surgery. When preliminary promising data on the value of surgery in recurrent ovarian cancer are confirmed in prospective randomized controlled trials (DESKTOP III trial, GOG 213 trial), early detection of recurrence by means of CA125 surveillance could become important. Third, there seems to be a tendency toward performing secondary cytoreductive surgery after some courses of “neo-adjuvant” chemotherapy,³ which was not allowed in the SOCceR trial. As long as there is no evidence for secondary cytoreductive surgery from randomized controlled trials, we believe that it is too early to adopt “interval” secondary cytoreductive surgery as a treatment option.

In conclusion, due to the premature stop of the SOCceR trial and, as a result, a low number of included patients, we are unable to determine the role of secondary cytoreductive surgery. We hope that the results of the DESPKTOP III study and the GOG 213 trial will demonstrate the role of secondary cytoreductive surgery in patients with recurrent platinum-sensitive epithelial ovarian.

Rafli van de Laar, MD

Department of Obstetrics and Gynecology
Radboud University Medical Centre
Nijmegen, the Netherlands
Department of Obstetrics and Gynecology
Maastricht University Medical Centre
Maastricht, the Netherlands

and GROW, School for Oncology
and Developmental Biology
Maastricht University
Maastricht, the Netherlands
raflivandelaar@hotmail.com

Roy F.P.M. Kruitwagen, MD, PhD

Department of Obstetrics and Gynecology
Maastricht University Medical Centre
Maastricht, the Netherlands
GROW, School for Oncology
and Developmental Biology
Maastricht University
Maastricht, the Netherlands

Petra L.M. Zusterzeel, MD, PhD

Department of Obstetrics and Gynecology
Radboud University Medical Centre
Nijmegen, the Netherlands

Toon Van Gorp, MD, PhD

Department of Obstetrics and Gynecology
Maastricht University Medical Centre
Maastricht, the Netherlands
GROW, School for Oncology
and Developmental Biology
Maastricht University
Maastricht, the Netherlands

Leon F.A.G. Massuger, MD, PhD

Department of Obstetrics and Gynecology
Radboud University Medical Centre
Nijmegen, the Netherlands

The authors declare no conflicts of interest.

REFERENCES

1. van de Laar R, Zusterzeel PL, Van Gorp T, et al. Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study. *BMC Cancer*. 2014;14:22.
2. Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. *Lancet*. 2010;376:1155–1163.
3. van de Laar R, Kruitwagen RF, IntHout J, et al. Surgery for recurrent epithelial ovarian cancer in the Netherlands: a population-based cohort study. *Int J Gynecol Cancer*. 2016;26:268–275.